BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

HanchorBio and Aston Sci Join Forces to Advance Dual-Action Cancer Immunotherapy Targeting Solid Tumours

Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...

October 26, 2026 | News

Tairex Unveils AI-Powered Agent Hospital Ecosystem to Transform Multidisciplinary Clinical Decision-Making

Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinar...

October 26, 2026 | News

Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

October 26, 2026 | News

ESTEVE CDMO Invests Over $80 Million to Expand Pharmaceutical Manufacturing Capabilities in China

After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. With more than $...

October 23, 2026 | News

Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer

Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...

October 23, 2026 | News

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

Chipscreen Biosciences Secures China IND Approval for First-in-Class Cancer Immunotherapy NW001

Shenzhen Chipscreen Biosciences Co., Ltd. announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with ...

October 21, 2026 | News

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Brii Biosciences Unveils Dual-Targeting siRNA Platform to Advance Next-Generation RNA Therapeutics

Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent me...

October 19, 2026 | News

Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals

ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (...

October 16, 2026 | News

Roche Secures Global Rights to Rona Therapeutics’ RNAi Obesity Candidate in Deal Worth Up to $1.16 Billion

- Rona Therapeutics announced it has granted Roche an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like...

October 15, 2026 | News

China’s Hiteck Biological Pharma Licenses Next-Generation Eye Therapy to Visara for Global Development

Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has entered into an exclusive license agreement (the "License Agreement") with Visara, Inc...

October 15, 2026 | News

Shanghai Ark Biopharmaceutical Secures US FDA IND Clearance for Phase II Trial of Long-Acting Influenza Prevention Drug AK0406

Shanghai Ark Biopharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK...

October 14, 2026 | News

Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...

October 13, 2026 | News

Stay Connected